Furthermore, analyses suggest SGLT2 inhibitors may offer renal protection even in acute settings, potentially mitigating AKI risk through hemodynamic stabilization and anti-inflammatory effects [42]. This evidence concerns the gene SLC5A2 and acute kidney injury.